Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug

Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming late-stage trial data for vepdegestrant, an experimental breast cancer therapy it co-develops with Pfizer (NYSE:PFE).

On Tuesday, based on data from those with estrogen receptor